HUTCHMED (China) Limited (HCM) RNS Announcements

Add to Alert list
Date Time Source Announcement
20 Oct 2015 02:40 PM
RNS
Director's Share Dealing
19 Oct 2015 07:00 AM
RNS
Awards under Long Term Incentive Plan
16 Oct 2015 12:17 PM
RNS
Shareholders' Circular and Notice of EGM
16 Oct 2015 12:15 PM
RNS
Filing of Registration Statement on Form F1
16 Oct 2015 12:03 PM
RNS
Chi-Med files Nasdaq Registration Statement
13 Oct 2015 07:00 AM
RNS
Enrolment complete in Savolitinib Phase II trial
12 Oct 2015 02:09 PM
RNS
Holding(s) in Company
14 Sep 2015 07:00 AM
RNS
Presentation at 2015 European Cancer Congress
02 Sep 2015 11:57 AM
RNS
Trial of fruquintinib achieves primary endpoint
19 Aug 2015 12:14 PM
RNS
Termination of R&D agreement with Janssen
28 Jul 2015 07:00 AM
RNS
Interim Results
23 Jul 2015 01:05 PM
RNS
Notification of major interest in shares
23 Jul 2015 01:01 PM
RNS
Notification of major interest in shares
23 Jul 2015 09:01 AM
RNS
Mitsui exchanges shares in Hutchison MediPharma
17 Jul 2015 07:00 AM
RNS
Invention patent granted for SXBXP
06 Jul 2015 07:00 AM
RNS
Notice of Announcement of 2015 Interim Results
29 Jun 2015 07:00 AM
RNS
Blocklisting Six Monthly Return
01 Jun 2015 07:00 AM
RNS
Savolitinib preliminary Phase Ib data presented
13 May 2015 07:00 AM
RNS
Fruquintinib results trigger payments from Lilly
30 Apr 2015 07:00 AM
RNS
Total Voting Rights
24 Apr 2015 12:40 PM
RNS
Result of AGM
22 Apr 2015 11:23 AM
RNS
Director/PDMR Shareholding
16 Apr 2015 01:19 PM
RNS
Director's Shareholding
13 Apr 2015 08:07 AM
RNS
Director's Shareholding
08 Apr 2015 08:18 AM
RNS
Directors' Shareholding
01 Apr 2015 03:48 PM
RNS
Directors Shareholding
01 Apr 2015 02:32 PM
RNS
Exercise of Options
30 Mar 2015 07:00 AM
RNS
Trial of fruquintinib achieves primary endpoint
23 Mar 2015 07:00 AM
RNS
Notice of AGM
18 Mar 2015 07:08 AM
RNS
Notification of Major Interest in Shares
06 Mar 2015 07:06 AM
RNS
Patient enrolment completion for Phase II study
26 Feb 2015 07:00 AM
RNS
Final Results
29 Jan 2015 07:00 AM
RNS
Distribution Agreement for Seroquel in China
26 Jan 2015 07:00 AM
RNS
Notice of Results
31 Dec 2014 07:00 AM
RNS
Total Voting Rights
29 Dec 2014 07:00 AM
RNS
Blocklisting Six Monthly Return
15 Dec 2014 07:00 AM
RNS
Initiation of fruquintinib Phase III study
20 Nov 2014 12:39 PM
RNS
Director's Shareholding
31 Oct 2014 07:03 AM
RNS
Total Voting Rights
07 Oct 2014 07:00 AM
RNS
Drug R&D Update Briefing
01 Oct 2014 07:00 AM
RNS
Co-promotion agreement with Merck Serono
19 Sep 2014 09:13 AM
RNS
Holding(s) in Company
21 Aug 2014 07:00 AM
RNS
Patient enrolment in Phase II study completed
13 Aug 2014 07:00 AM
RNS
HMPL-004 Interim Analysis
29 Jul 2014 07:00 AM
RNS
Interim Results
30 Jun 2014 07:00 AM
RNS
Blocklisting Interim Review
30 Jun 2014 07:00 AM
RNS
Total Voting Rights
26 Jun 2014 07:00 AM
RNS
Notice of Results
25 Jun 2014 07:00 AM
RNS
Chi-Med Refinancing of Existing Loan Facility
18 Jun 2014 07:00 AM
RNS
Start of Phase I clinical trial with HMPL-523

Hutchmed China  Limited develops, manufactures, and sells pharmaceutical products. The Company offers drugs for oncology and autoimmune diseases treatment. HUTCHMED (China) is headquartered in Hong Kong and markets its products worldwide.

It was founded in 2000 and listed in London in 2018 under the ticker HCM. 

UK 100

Latest directors dealings